Ticagrelor

Platelet inhibition strategies in people with MI undergoing PCI.

Compared with aspirin alone, aspirin plus ticagrelor was associated with reduced risk for vein graft failure and increased risk for clinically important bleeding in patients who underwent CABG, according to a meta-analysis.

In this edition, Break Through Cancer awards $50M to fund a ‘radical collaboration’ in cancer research; the FDA grants a breakthrough device designation for an MS plasma test; App-based mental exercises may improve cognitive impairment; and more.

Concomitant proton pump inhibitor plus ticagrelor monotherapy after PCI does not increase risk for all-cause death or an adverse CV event, in contrast with conventional post-PCI antiplatelet therapy, researchers reported.

The benefits of ticagrelor and aspirin outweighed the risk for major hemorrhage in patients with mild to moderate ischemic stroke or at high risk for transient ischemic attack during 30 days of treatment, according to a Neurology study.

WASHINGTON — The IV monoclonal antibody bentracimab immediately and significantly reversed the antiplatelet effect of ticagrelor in healthy older adults, with no related serious adverse events, researchers reported.

In patients requiring secondary CVD prevention, P2Y12 inhibitor monotherapy conferred reduced risk for major adverse CV events compared with aspirin monotherapy without raising risk for bleeding, researchers reported.

Bentracimab (PhaseBio) for reversal of ticagrelor (Brilinta, AstraZeneca) in patients with uncontrolled major or life-threatening bleeding or undergoing an urgent invasive procedure.

P2Y12 inhibitor plus anti-coagulation vs. anticoagulation alone in noncritically ill patients with COVID-19.

Ticagrelor monotherapy after 3 months of dual antiplatelet therapy lowered the incidence of major bleeding events vs. continued DAPT among patients with high bleeding risk who underwent PCI, according to new insights from TWILIGHT.